Osteonecrosis is a disease in which bone cells dies or bones collapse due to lack of blood flow to the bones. It is also known as avascular necrosis, aseptic necrosis or ischemic necrosis. Osteonecrosis is most commonly developed in hip bone (femur) or knees, while less often in shoulder, wrist, ankle, hands, and feet. It can cause mild to severe pain and may lead to micro-fracture. Osteonecrosis can be diagnosed by using X-ray, CT scan, MRI, bone scan, and functional bone tests. Osteonecrosis treatment targets symptoms and reduces pain via medication or surgery in extreme cases. According to the National Organization for Rare Disorders, osteonecrosis is one of the rare diseases, where less than 1 in 2000 are only affected by this disorder. In 2017, Bone Therapeutics reported that around 170,000 patients were suffering from osteonecrosis in Europe, the U.S., and Japan. The advancements in treatment technologies and gene therapy and stem cell based osteonecrosis treatment are expected to propel growth of the osteonecrosis treatment market.
Osteonecrosis Treatment Market Taxonomy
By Drug Class
By Distribution Channels
Osteonecrosis Treatment Market Driver
Advanced Therapy Medicinal Products (ATMPs) to boost osteonecrosis treatment market. Advanced Therapy Medicinal Products is a class of innovative therapies that comprises of gene therapy, somatic cell therapy, and tissue-engineered products, which is expected to drive growth of osteonecrosis treatment market. Osteonecrosis usually affects young population and this significantly will contributes towards growth of osteonecrosis treatment market. For instance, according to the American College of Rheumatology, in 2017, around 10,000 to 20,000 people in the U.S. who suffered from osteonecrosis were between the ages of 20 and 50. Currently, the osteonecrosis non-surgical treatment (medication) is symptomatic treatment that targets the symptoms and try to cure the disease. Hence, emerging players in the field of bone disease treatment is gaining momentum by introducing gene regulation approach. Key players like Enzo Biochem, Inc. and Bone Therapeutics are aiming gene regulation and cell-based product treatment, which is expected to augment growth of osteonecrosis treatment market. For instance, PREOB manufactured by Bone Therapeutics, a cell based medicinal product derived from autologous bone marrow stem cells has been approved in the U.S., however, it is currently in phase III in Europe.
In spite of being a rare disease, osteonecrosis treatment market is expected to propel due to the prevalence of causative agent for osteonecrosis. Side effects of various medicines taken during cancer, HIV/AIDS, osteoarthritis, osteoporosis or blood disorders or medical treatment such as chemotherapy, radiation therapy, high-dosage of steroids or organ transplants may increases the chances of having osteonecrosis. Furthermore, few interventions such as Stanford University’s sponsored project aims at evaluation of osteonecrosis before and after decompression surgery with ferumoxytol-enhanced MRI, which improve detection and allow to track transplanted bone marrow cells. This intervention is in phase 4 clinical trial and is expected to complete the project over the forecast period, which in turn will propel growth of the osteonecrosis treatment market.
Osteonecrosis Treatment Market – Regional Analysis
On the basis of region, the global osteonecrosis treatment market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold a dominant position in the global osteonecrosis treatment market over the forecast period due to increasing prevalence pool of osteonecrosis, prior Food and Drug Administration (FDA) approval for the new treatments in this region. For instance, according to NCBI 2015, it is estimated that around 20,000 to 30,000 new patients are diagnosed with osteonecrosis annually in the U.S. Asia Pacific is also expected to witness faster growth in the global osteonecrosis treatment market over the forecast period, owing to increase in development activities by various key players in this region. For instance, Bone Therapeutics and Asahi Kasei Corporation signed a license agreement in 2017 for the development and commercialization of PREOB in Japan.
Osteonecrosis Treatment Market – Competitor
Major players involved in osteonecrosis treatment market include Bone Therapeutics, Enzo Biochem Inc., and K-Stemcell Co Ltd. Hospitals, clinics, universities, and institutes are other major participants in the osteonecrosis treatment market.